AEON Biopharma presents corporate update at Aegis Capital Conference, focusing on PrabotulinumtoxinA

AEON Biopharma, Inc.

Presentation highlights PrabotulinumtoxinA as a therapeutic botulinum toxin product candidate.
Corporate presentation made available on AEON's investor relations website on May 20, 2025.
No specific clinical data, financial results, or material changes disclosed in the furnished slides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.